logo
Roper Technologies to acquire CentralReach

Roper Technologies to acquire CentralReach

Yahoo24-03-2025

Leading provider of SaaS solutions for Applied Behavior Analysis therapy
SARASOTA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) today announced that it has reached a definitive agreement to acquire CentralReach from Insight Partners for a net purchase price of approximately $1.65 billion, including a $200 million tax benefit resulting from the transaction. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth.
CentralReach is a leading provider of cloud-native software enabling the workflow and administration of Applied Behavior Analysis ('ABA') therapy. Over 200,000 professionals utilize CentralReach's purpose-built solutions to help provide care for individuals with autism spectrum disorder ('ASD') and related intellectual and developmental disabilities ('IDD'). ABA therapy providers rely on CentralReach's comprehensive electronic medical records platform as their mission critical operating system, which includes highly specialized tools for client set-up, practice management, claims processing, care scheduling, clinical data collection, and service delivery, along with several AI-powered add-on modules.
'CentralReach is a fantastic business with clear niche market leadership, mission critical and high ROI solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion,' said Neil Hunn, Roper's President and CEO. 'This acquisition is another example of Roper identifying a business that provides greater value creation for our shareholders. CentralReach meets each of our long-standing acquisition criteria, while also having a structurally faster organic growth profile and the ability to expand margins under Roper's long-term ownership. We are excited to welcome the CentralReach team to the Roper family and look forward to partnering with the team to execute their strategy.'
Acquisition financial outlook and financing
CentralReach is expected to contribute approximately $175 million of revenue and $75 million of EBITDA for the twelve months ending June 30, 2026, and will be reported in Roper's Application Software segment. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth.
The transaction is expected to close in April/May 2025, subject to regulatory approval and customary closing conditions, and will be funded using Roper's revolving credit facility. Additional information about CentralReach is available in the Investors section of Roper's website (www.ropertech.com).Roper supplements its consolidated financial statements presented on a GAAP basis with certain non-GAAP financial information, including EBITDA, to provide investors with greater insight, increase transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Roper defines EBITDA as earnings before interest, taxes, depreciation, and amortization. Roper has not provided a reconciliation of the expected EBITDA contribution by CentralReach to the expected net income contribution by CentralReach for the twelve months ending June 30, 2026 because we are unable to quantify certain amounts that would be required to be included in CentralReach's contribution to net income without unreasonable efforts. In addition, Roper believes such reconciliation would imply a degree of precision that would be confusing or misleading to investors. The non-GAAP financial measure disclosed by Roper in this press release should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP, and the financial results prepared in accordance with GAAP and reconciliations from these results should be carefully evaluated.
About Roper Technologies
Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company's website at www.ropertech.com.
About CentralReach
CentralReach is a leading provider of Autism and IDD Care Software, providing a complete, end-to-end software and services platform that helps therapists who serve children and adults diagnosed with autism spectrum disorder (ASD) and related intellectual and developmental disabilities (IDD). With its roots in Applied Behavior Analysis, the company is revolutionizing how the lifelong journey of autism and IDD care is enabled at home, school, and work with powerful and intuitive solutions purpose-built for each care setting.
Trusted by more than 200,000 professionals globally, CentralReach is committed to ongoing product advancement, market-leading industry expertise, world-class client satisfaction, and support of the autism and IDD community to propel autism and IDD care into a new era of excellence. For more information, please visit www.CentralReach.com.
Contact information: Investor Relations941-556-2601 investor-relations@ropertech.com
The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, acquired businesses, including obtaining any required regulatory approvals with respect thereto. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, including risks related to labor shortages and rising interest rates, changes in foreign exchange rates, risks related to changing U.S. and foreign trade policies, including increased trade restrictions or tariffs, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19 pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of inflation and potential supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.Sign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US stock futures little changed as investors await US-China trade talk news
US stock futures little changed as investors await US-China trade talk news

USA Today

time35 minutes ago

  • USA Today

US stock futures little changed as investors await US-China trade talk news

US stock futures little changed as investors await US-China trade talk news Show Caption Hide Caption How fentanyl reaches the US and the role of Trump's China tariffs US President Donald Trump has imposed new tariffs on Chinese goods, citing Beijing's failure to stop the export of chemicals used to produce fentanyl. unbranded - Newsworthy U.S. stock futures are little changed as investors continue to wait for news from U.S.-China trade talks in London. Talks are expected to continue for a second day. Earlier, Kevin Hassett, director of the National Economic Council, said he expected an agreement to emerge that would loosen controls on U.S. exports of semiconductors in exchange for China's releasing of more rare earths. The London talks follow a phone call between President Donald Trump and Chinese leader Xi Jinping, the first between the two since Trump took office and after Trump accused China of violating terms of a tariff pause agreed upon in Switzerland last month. At 6:45 a.m. ET, futures on the blue-chip Dow dropped -0.06%, while broad S&P 500 futures added 0.06% and tech-laden Nasdaq futures rose 0.09%. Later this week, investors will see May inflation data. The May reports will reflect the first full month of price changes since Trump announced aggressive tariffs on April 2. Since then, many of the highest tariffs have been put on ice but others have gone into effect. Corporate news Cracker Barrel Old Country Store said it plans to sell $275 million in convertible senior notes due in 2030 in a private offering. Limoneira said its fiscal second quarter results were worse than in the year-ago period. Cryptocurrency Paraguay President Santiago Pena's X account had likely been hacked to say that the Latin American country had made Bitcoin legal tender and that it would roll out a $5 million Bitcoin-backed reserve fund. The post was deleted and the government said "the president's official X account has presented irregular activity which suggests possible unauthorized entry." Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning.

Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Announces Annual Meeting of Shareholders

Yahoo

time36 minutes ago

  • Yahoo

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the 'Investors' section of Pharvaris' website under 'Events & Presentations'. The documents will also be made available on the SEC's website at Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting. About PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit CONTACT: Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications

US stock futures little changed as investors await US-China trade talk news
US stock futures little changed as investors await US-China trade talk news

Yahoo

time36 minutes ago

  • Yahoo

US stock futures little changed as investors await US-China trade talk news

U.S. stock futures are little changed as investors continue to wait for news from U.S.-China trade talks in London. Talks are expected to continue for a second day. Earlier, Kevin Hassett, director of the National Economic Council, said he expected an agreement to emerge that would loosen controls on U.S. exports of semiconductors in exchange for China's releasing of more rare earths. The London talks follow a phone call between President Donald Trump and Chinese leader Xi Jinping, the first between the two since Trump took office and after Trump accused China of violating terms of a tariff pause agreed upon in Switzerland last month. At 6:45 a.m. ET, futures on the blue-chip Dow dropped -0.06%, while broad S&P 500 futures added 0.06% and tech-laden Nasdaq futures rose 0.09%. Later this week, investors will see May inflation data. The May reports will reflect the first full month of price changes since Trump announced aggressive tariffs on April 2. Since then, many of the highest tariffs have been put on ice but others have gone into effect. Cracker Barrel Old Country Store said it plans to sell $275 million in convertible senior notes due in 2030 in a private offering. Limoneira said its fiscal second quarter results were worse than in the year-ago period. Paraguay President Santiago Pena's X account had likely been hacked to say that the Latin American country had made Bitcoin legal tender and that it would roll out a $5 million Bitcoin-backed reserve fund. The post was deleted and the government said "the president's official X account has presented irregular activity which suggests possible unauthorized entry." Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning. This article originally appeared on USA TODAY: US stock futures little changed amid US-China trade talks

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store